liveBook · Manning

Generative chemistry

As explained in Build AI Drug Discovery Pipelines

Generative molecular design is the computational creation of molecular structures intended to satisfy specified biological, chemical, or medicinal requirements.

Generative chemistry uses computational models to create novel molecular structures that satisfy biological, chemical, or medicinal requirements. In de novo design, the process starts with desired properties rather than an existing molecular library, addressing the difficulty of optimizing solubility, toxicity, pharmacokinetics, and therapeutic activity simultaneously. section 1.3.2 section 10.1.1

A generative chemistry workflow is framed around three ideas:

  • Specify property criteria, such as high solubility and low toxicity, instead of beginning with a fixed compound library. section 1.3.2
  • Use a generative model to map desired functional properties back to candidate structures in chemical space. section 1.3.2 section 10.1
  • Score proposed molecules with property-prediction models, while checking for weaknesses such as instability, impractical synthesis, unrealistic structures, and reward hacking. section 1.3.2

Choosing a design strategy

When both a ligand structure and its target are known, structure-based design is available. Knowing only the ligand supports ligand-based design; knowing only the target can support de novo generation of a candidate. section 1.3.2

Figure 1.9 In virtual screening, we start with a large, diverse library of compounds that we can filter using a predictive model that has learned to predict what properties each compound has. Our predictive model has learned how to map the chemical space to the functional space. If the compound is predicted to have optimal properties, we carry it over for further experiments. In de novo design, we start with a defined set of property criteria that we can use along with a generative model to generate the structure of our ideal drug candidate. Our generative model knows how to map the functional space to the chemical space.

Compare virtual screening, which filters an existing chemical library, with de novo design, which uses property criteria to generate molecular structures. section 1.3.2

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains de novo design, functional-to-chemical mapping, latent space, and scoring risks without providing implementation details.
Examples
Uses property criteria, generated candidate structures, solubility and toxicity goals, and ligand–target knowledge to distinguish design strategies.
What you can do after
Evaluate/understand how de novo models reverse-engineer candidate structures from desired molecular properties and where scoring can fail.
How it connects
Connects virtual screening, chemical space, functional space, property prediction, latent space, and drug discovery.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.